For the Inventor, By the Inventor

Enter assignee name

Kenilworth, NJ, United States of America

Schering Corporation

USPTO Granted Patents = 1,829

CIPO Patents = 346

EPO Patents = 118

Trademarks = 152

Forward Citations = 23,138

Loading Chart...

Loading Chart...

1,549 inventors (with patents filed for the assignee):

Viyyoor Moopil Girijavallabhan (127 out of 130 patents)

Ashit K Ganguly (104 out of 106 patents)

Ronald J Doll (92 out of 105 patents)

4. Neng-Yang Shih (80 out of 110 patents)

5. F George Njoroge (71 out of 99 patents)

6. Bernard R Neustadt (68 out of 77 patents)

7. Anil K Saksena (59 out of 61 patents)

8. Alan K Mallams (59 out of 61 patents)

9. John J Piwinski (51 out of 71 patents)

10. Samuel Chackalamannil (50 out of 77 patents)

11. Joseph A Kozlowski (50 out of 104 patents)

12. Timothy J Guzi (50 out of 64 patents)

13. John W Clader (50 out of 59 patents)

14. Stuart W McCombie (48 out of 48 patents)

15. Brian Alexander McKittrick (47 out of 68 patents)

Core Competencies:

CX3C Chemokines

Anti-IL-23 Antibodies

Himbacine Analogs

CD200 Receptors

Protein Kinase Inhibitors

Bispecific Antibodies

VEGF Antibodies

CXC-Chemokine Receptor Ligands

IL-17A Antibodies

Inflammatory Disorders

Thrombin Receptor Antagonists

Hepatitis C Virus Inhibitors

1,829 patents: Sort by Forward Citations

1. 8343492 - Method for blocking binding of CX3C chemokines using CX3C chemokine antibodies (2013-01-01),

2. 8293883 - Engineered anti-IL-23P19 antibodies (2012-10-23),

3. 8273790 - Exo-selective synthesis of himbacine analogs (2012-09-25),

4. 8263748 - Lyophilized formulations of engineered anti-IL-23p19 antibodies (2012-09-11),

5. 8263080 - Use of agonists and antagonists of IL-23 in the treatment of viral infection (2012-09-11),

6. 8263070 - Methods of modulating CD200 receptors (2012-09-11),

7. 8258319 - Exo- and diastereo- selective synthesis of himbacine analogs (2012-09-04),

8. 8257921 - NRIP1 regulation of apolipoprotein A1 (2012-09-04),

9. 8242112 - Heterocyclic aspartyl protease inhibitors (2012-08-14),

10. 8236309 - Use of bispecific antibodies to regulate immune responses (2012-08-07),

11. 8232372 - Engineered anti-TSLP antibody (2012-07-31),

12. 8227605 - 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors (2012-07-24),

13. 8226947 - Interleukin-10 antibodies (2012-07-24),

14. 8222259 - [object Object] (2012-07-17),

15. 8216571 - Fully human anti-VEGF antibodies and methods of using (2012-07-10),

Schering Corporation is a global pharmaceutical company specializing in the development, production, and marketing of innovative healthcare solutions. With a commitment to improving human health, Schering Corporation focuses on research in various therapeutic areas, including cardiovascular, oncology, immunology, and women's health. Through strategic partnerships and collaborations, Schering Corporation aims to provide patients with access to life-changing medications and treatments.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

1,829 Patents

#1 in Kenilworth, NJ

#17 in New Jersey

#273 in US

#536 in the World

Kenilworth, NJ, United States of America

Schering Corporation

Forward Citations = 23,138

1,549 inventors:

Viyyoor Moopil Girijavallabhan (127 out of 130 patents)

Ashit K Ganguly (104 out of 106 patents)

Ronald J Doll (92 out of 105 patents)

4. Neng-Yang Shih (80 out of 110 patents)

5. F George Njoroge (71 out of 99 patents)

Please report any incorrect information to support@idiyas.com

Loading…